Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, ...

Chugai Pharm signs collaboration agreement with GSK's Global Health Unit for development of anti-dengue virus antibody: Tokyo Friday, January 31, 2025, 09:00 Hrs [IST] Chugai Phar ...

Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Genmab A/S (NASDAQ:GMAB), a Danish biotechnology company specializing in antibody therapeutics for cancer treatment, finds itself at a crucial juncture. With a strong portfolio of approved medicines ...

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...

The global silicone additives market is expected to grow at 7% CAGR from 2024 to 2030. It is expected to reach above USD 2.70 billion by 2030 from USD 1.47 billion in 2023. Explore core findings and ...

BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Tissue processing advance can label proteins at the level of individual cells across whole, intact rodent brains and other ...

New research emphasizes the need for ongoing COVID-19 protection for people with weakened immune systems, with scalable tests ...

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...